uniQure N.V. QURE
We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntington's disease, refractory mesial temporal lobe epilepsy ("MTLE"), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 ("SOD1-ALS").
In September 2025, we announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease. We analyzed clinical outcomes for 29 patients treated with AMT-130 (n=17 high-dose; n=12 low-dose) of which 12 patients per dose group had attained 36 months of follow-up and were evaluated at that time point. Outcomes for each dose group were compared to a propensity score-matched external control drawn from the Enroll-HD natural history data set (n=940 for high-dose; n=626 for low-dose).
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M | $524.0M | $37.5M | $7.3M | $11.3M | $13.1M | $25.1M |
| Cost of revenue | $1.7M | $1.3M | $65.0K | $1.3M | $25.0M | $2.9M | $1.7M | $1.2M | $817.0K | $1.3M |
| Gross profit | $14.4M | $25.9M | $15.8M | $105.2M | $499.0M | $34.6M | $5.6M | $10.1M | $12.3M | $23.8M |
| R&D | $140.7M | $143.8M | $214.9M | $197.6M | $143.5M | $122.4M | $94.7M | $74.8M | $72.2M | $72.5M |
| SG&A | $65.5M | $52.7M | $74.6M | $55.1M | $56.3M | $42.6M | $33.5M | $25.3M | $24.6M | $26.0M |
| Total operating expenses | $207.8M | $214.8M | $303.1M | $256.0M | $224.8M | $165.0M | $128.3M | $100.1M | $96.8M | $98.5M |
| Operating income | -$185.3M | -$184.3M | -$282.9M | -$143.2M | $310.6M | -$125.4M | -$121.1M | -$88.2M | -$71.3M | -$71.9M |
| Interest expense | $62.0M | $63.7M | $41.6M | $11.7M | $7.5M | $3.8M | $3.8M | $2.2M | $2.2M | $2.2M |
| Pre-tax income | -$193.3M | -$237.1M | -$306.6M | -$128.3M | $332.8M | -$141.4M | -$124.2M | -$83.1M | -$79.5M | -$72.2M |
| Income tax | $5.6M | $2.4M | $1.9M | $1.5M | $3.2M | $16.4M | — | $231.0K | $199.0K | $1.1M |
| Net income | -$199.0M | -$239.6M | -$308.5M | -$126.8M | $329.6M | -$125.0M | -$124.2M | -$83.3M | -$79.3M | -$73.4M |
| EPS, basic | -3.46 | -4.92 | -6.47 | -2.71 | 7.17 | -2.81 | -3.11 | — | — | — |
| EPS, diluted | -3.46 | -4.92 | -6.47 | -2.71 | 7.04 | -2.81 | -3.11 | -2,340.00 | -2,940.00 | -2.93 |
| Shares, diluted (wtd. avg.) | $57.5M | $48.6M | $47.7M | $46.7M | $46.8M | $44.5M | $40.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $80.2M | $158.9M | $241.4M | $231.2M | $559.4M | $247.7M | $380.7M | $237.3M | $161.9M | $134.3M |
| Receivables | — | — | — | — | — | $6.6M | — | — | — | $3.7M |
| Inventory | — | — | $12.0M | $6.9M | — | — | — | — | — | — |
| Total current assets | $656.0M | $390.3M | $651.9M | $476.8M | $628.2M | $258.9M | $384.2M | $236.6M | $162.8M | $143.9M |
| Property, plant and equipment | $13.8M | $20.4M | $46.5M | $50.5M | $43.5M | $32.3M | $28.8M | $29.2M | $34.3M | $35.7M |
| Goodwill | $25.4M | $22.4M | $26.4M | $25.6M | $27.6M | $542.0K | $496.0K | $506.0K | $530.0K | $465.0K |
| Other intangibles | $72.8M | $71.0M | $60.5M | $58.8M | $62.7M | $3.4M | $5.4M | $5.2M | $9.6M | $8.3M |
| Total assets | $824.9M | $556.5M | $831.7M | $705.0M | $809.2M | $340.4M | $448.6M | $273.9M | $209.6M | $190.3M |
| Accounts payable | $5.2M | $7.2M | $6.6M | $11.0M | $2.5M | $3.8M | $5.7M | $3.8M | $2.9M | $5.5M |
| Short-term debt | — | — | — | — | — | — | — | — | $1.1M | $605.0K |
| Total current liabilities | $62.9M | $40.1M | $73.7M | $75.9M | $36.8M | $27.3M | $31.6M | $20.0M | $19.2M | $22.7M |
| Long-term debt | $49.7M | $51.3M | $101.7M | $102.8M | $101.0M | $35.6M | $36.1M | $35.5M | $19.7M | $19.6M |
| Total liabilities | $626.0M | $563.3M | $624.0M | $229.0M | $213.4M | $96.5M | $125.6M | $94.3M | $120.3M | $126.6M |
| Retained earnings | -$1.33B | -$1.13B | -$890.4M | -$581.9M | -$455.1M | -$784.7M | -$659.7M | -$535.5M | -$475.3M | -$396.1M |
| Total equity | $198.9M | -$6.8M | $207.7M | $476.0M | $595.8M | $243.9M | $323.1M | $179.6M | $89.4M | $63.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$178.0M | -$182.7M | -$145.9M | -$145.1M | $288.0M | -$134.8M | -$98.7M | -$76.0M | -$64.3M | -$72.2M |
| Depreciation and amortisation | $9.1M | $10.1M | $10.3M | $8.2M | $6.1M | $5.7M | $6.0M | $6.5M | $7.0M | $5.5M |
| Stock-based compensation | $17.7M | $22.3M | $35.1M | $34.2M | $25.6M | $21.8M | $17.5M | $10.7M | $10.3M | $6.2M |
| Capital expenditure | $439.0K | $3.4M | $7.2M | $17.7M | $17.4M | $7.3M | $5.7M | $2.4M | $4.5M | $15.3M |
| Investing cash flow | -$321.6M | $163.0M | -$205.7M | -$182.7M | -$67.4M | -$9.5M | -$6.6M | -$4.2M | -$5.6M | -$17.2M |
| Financing cash flow | $415.4M | -$59.5M | $362.7M | $1.4M | $94.9M | $7.4M | $248.8M | $158.0M | $90.1M | $2.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-048969.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |